(5α,6α)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triolhydrochlorid Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R26/27/28:Sehr giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Verwenden
Nalbuphine is the free base form of Nalbuphine Hydrochloride. Nalbuphine is a mixed opioid agonist-antagonist. Nalbuphine is an analgesic (narcotic).
Acquired resistance
Nalbuphine is an antagonist at μ receptors and an agonist at κ receptors. As an
antagonist, it has approximately one-fourth the potency of naloxone, and it produces withdrawal
when given to addicts. On a weight basis, the analgesic potency of nalbuphine
approaches that of morphine. An intramuscular injection of 10 mg will give about the same degree
and duration of analgesia as an equivalent dose of morphine.
Clinical Use
Nalbuphine is only available for parenteral dosage. Its elimination half-life is 2 to 3 hours.
Metabolism of nalbuphine is by conjugation of the 3-OH group, and greater than 90% of the drug is
excreted as conjugates in the feces.
Nebenwirkungen
Side effects of nalbuphine are like those of other κ. Dysphoria is not as common as with
pentazocine. Sedation is the most common side effect. Nalbuphine does not have the adverse
cardiovascular properties found with pentazocine and butorphanol. Nalbuphine has low abuse
potential and is not listed under the Controlled Substances Act.
(5α,6α)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triolhydrochlorid Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
